CERS Stock Analysis: Buy, Sell, or Hold?
CERS - Cerus Corp
$2.15
0.00 (0.00%)
▲
5d:
-29.97%
30d:
-31.96%
90d:
-20.96%
WAIT
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Jul 30, 2026
0d
Get Alerted When CERS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CERS is down 30.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CERS is down 30.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: CERS is currently trading at $2.15, which is considered oversold relative to its 30-day fair value range of $2.72 to $3.25. From a valuation perspective, the stock is trading at a discount (Forward PE: 71.7) compared to its historical average (81.2). Remarkably, the market is currently pricing in an annual earnings decline of 4.1% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, CERS is in a strong uptrend. Immediate support is located at $2.06, while resistance sits at $3.22.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.50 (+109.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CERS is in a strong uptrend. Immediate support is located at $2.06, while resistance sits at $3.22.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.50 (+109.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.72 -
$3.25
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 109.3% below Wall St target ($4.50)
- WARNING: Recommendation downgraded due to -30.0% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$2.72 -
$3.25
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.06
Resistance Level
$3.22
Current Trend
Strong Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
71.67
Wall Street Target
$4.50
(+109.3%)
Revenue Growth (YoY)
9.5%
Profit Margin
-3.1%
Valuation Discount vs History
-4.1% cheaper
PE vs Historical
71.7 vs 81.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.1%
(market-implied from PE analysis)
1-Year Target
$2.06
(-4%)
2-Year Target
$1.98
(-8%)
3-Year Target
$1.90
(-12%)
3-Yr Target (if PE normalizes)
(PE: 72→81)
$2.15
(0%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 71.7 to 81.2
Stabilization Target:
$2.44
(+13.3%)
PE Expansion Potential:
+13.3%
Share & Embed Analysis
Last updated: August 03, 2026 6:10 PM ET
Data refreshes hourly during market hours. Next update: 7:10 PM
Data refreshes hourly during market hours. Next update: 7:10 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CERS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
12
Sells
Net
INSIDERS SELLING
Recent Transactions
Kevin Dennis Green
SELL
127544 shares
2026-03-12
Richard J Benjamin
SELL
101740 shares
2026-03-12
Vivek K Jayaraman
SELL
165200 shares
2026-03-12
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$64 | 55 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$384 | 51 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$118 | 52 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$98 | 57 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$236 | 51 HOLD |
